sacituzumab tirumotecan SKB264
Selected indexed studies
- Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials. (Nat Med, 2025) [PMID:40210967]
- First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial. (Nat Med, 2025) [PMID:40830660]
- Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences. (Cancer Chemother Pharmacol, 2025) [PMID:41258931]
_Worker-drafted node — pending editorial review._
Connections
sacituzumab tirumotecan SKB264 is a side effect of
Sources
- Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials. (2025) pubmed
- First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial. (2025) pubmed
- Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences. (2025) pubmed
- Therapeutic Applications and Target Strategies of Antibody-Drug Conjugates in Ovarian Cancer. (2025) pubmed
- Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody-drug conjugate in breast cancer. (2026) pubmed